

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Klein Lawrence Otto</u>			2. Issuer Name and Ticker or Trading Symbol <u>CRISPR Therapeutics AG [CRSP]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <u>CBO & COO</u> Other (specify below) _____		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>01/15/2021</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>CAMBRIDGE MA 02139</u>								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	01/15/2021		M		8,666	A	\$12.57	28,666	D	
Common Shares	01/15/2021		S ⁽¹⁾		2,911	D	\$211.44 ⁽²⁾	25,755	D	
Common Shares	01/15/2021		S ⁽¹⁾		2,555	D	\$212.54 ⁽³⁾	23,200	D	
Common Shares	01/15/2021		S ⁽¹⁾		1,200	D	\$213.71 ⁽⁴⁾	22,000	D	
Common Shares	01/15/2021		S ⁽¹⁾		1,400	D	\$214.46 ⁽⁵⁾	20,600	D	
Common Shares	01/15/2021		S ⁽¹⁾		400	D	\$216.24 ⁽⁶⁾	20,200	D	
Common Shares	01/15/2021		S ⁽¹⁾		200	D	\$217.45 ⁽⁷⁾	20,000	D	
Common Shares	01/15/2021		M		16,344	A	\$14.43	36,334	D	
Common Shares	01/15/2021		S ⁽¹⁾		634	D	\$212.2 ⁽⁸⁾	35,700	D	
Common Shares	01/15/2021		S ⁽¹⁾		2,800	D	\$213.64 ⁽⁹⁾	32,900	D	
Common Shares	01/15/2021		S ⁽¹⁾		700	D	\$214.6 ⁽¹⁰⁾	32,200	D	
Common Shares	01/15/2021		S ⁽¹⁾		1,500	D	\$216.39 ⁽¹¹⁾	30,700	D	
Common Shares	01/15/2021		S ⁽¹⁾		9,997	D	\$217.42 ⁽¹²⁾	20,703	D	
Common Shares	01/15/2021		S ⁽¹⁾		701	D	\$218.54 ⁽¹³⁾	20,002	D	
Common Shares	01/15/2021		S ⁽¹⁾		2	D	\$219.99 ⁽¹⁴⁾	20,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$12.57	01/15/2021		M			8,666	(15)	07/14/2026	Common Shares	8,666	\$0.00	0	D	
Stock Option (Right to Buy)	\$14.43	01/15/2021		M			16,334	(16)	06/14/2027	Common Shares	16,334	\$0.00	14,666	D	

Explanation of Responses:

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$211.01 to \$212.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$212.01 to \$212.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$213.10 to \$214.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$214.125 to \$214.75, inclusive. The reporting person undertakes to provide

